AMYPAD announces Last Patient Out in its Prognostic Study

On the 30th of June, the members of the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) project announced the completion of the last patient visit in its Prognostic and Natural History Study (PNHS). All sites have been done with the recruitment and scanning of participants, which represents an important milestone.

The PNHS study is an open-label, prospective and multi-centre cohort study aiming to understand the role of amyloid PET imaging in the earliest stages of Alzheimer’s disease (AD). The first participant was recruited in Amsterdam, The Netherlands, in October 2018.

The study has been established to collect amyloid PET scans in a large-scale population in the early stages of AD. The study recruited participants from various European parent cohorts of similar characteristics. The main and original parent cohort was the European Prevention of Alzheimer’s Dementia (EPAD) due to the inherent collaborative framework between the two projects. With this EPAD partnership, the PNHS study was active in a total of 17 sites across 7 European countries (VUmc, Amsterdam; UEDIN, Edinburgh; BBRC, Barcelona; CHUT, Toulouse; UNIGE, Geneva; CHU Montpellier; NHS Tayside; Hôpital Pitié-Salpêtriere, Paris; UZ Leuven; Hôpital Lariboisière, Paris; KI, Stockholm; CHU Nantes; CITA, San Sebastian; Fundacio ACE, Barcelona; CHU Lille; UC Louvain; UGOT, Gothenburg).
In addition to EPAD, there were 9 other Parent Cohorts actively recruiting into AMYPAD. These are:  EMIF-AD (60++ and 90+), ALFA+, FACEHBI, FPACK, UCL 2010-412, Microbiota, AMYPAD DPMS (VUMC) and H70.

On the 30th of April the recruitment was formally ended and the study succeeded in recruiting 1,321 participants. The final scans were performed in June and the Last Patient Out date was the 30th of June 2022. The number of prospective scans collected within AMYPAD PNHS is 1,419 (1,192 baseline and 227 follow-up). The non EPAD Parent Cohorts also shared their historical data and therewith the total number of scans in AMYPAD PNHS is over 2700.  We might have more data if additional projects would join after the project ends. Two additional Parent Cohorts have already expressed interest in joining forces after the IMI-funding period. At this moment, the AMYPAD team is focused on the close out of the sites and the last closure visit is scheduled for September 2022.

If you are interested to know more about the PNHS study including highlights and challenges, watch the interview below with the PNHS clinical trial managers Ifrah Iidow and Ilona Bader:

The consortium would like to thank all study centres and research participants for their time and commitment.

AMYPAD announces Last Patient Out in its Prognostic Study
More News